Literature DB >> 8722746

Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry.

H Anton-Culver1, T Kurosaki, T H Taylor, M Gildea, D Brunner, D Bringman.   

Abstract

A major risk factor for breast cancer is family history of the disease in first-degree relatives. This study evaluates the validity of family history information on breast cancer in mothers and sisters of breast cancer probands from the cancer registry (CR) compared to personal interviews (PI) of 359 consecutive population-based cases of breast cancer. Breast cancer is seen in mothers of 14% of probands by CR compared to 12% by PI. Further, 13% of probands have a sister with breast cancer using CR compared to 12% by PI. Using PI as the standard, the sensitivity of the CR family history data in mothers is 92% and the specificity is 99%, while in sisters they are 88% and 99%, respectively. These estimates were calculated on cases where family history information is available in the CR. Sensitivity and specificity are recalculated, recording an "error" whenever family history information is not available, and they are 75% and 68%, respectively, for mothers and 72% and 70%, respectively, for sisters. Estimates of proband-mother and proband-sisters familial breast cancer from CR and PI are sufficiently similar to warrant the use of CR family history data in studies of genetic epidemiology. The family phenotype consistent with the BRCA1 syndrome was found in four (1.1%) probands, all below age 50 years, while for BRCA2 there were five (1.4%) probands, three below age 50 years and two 50 years or older. Site-specific familial breast cancer was found in 23 (6.4%) probands. Population-based multiple-case breast cancer families can rapidly be identified through CR. These families can make substantial contributions to the study of genetic and environmental etiology of the disease as well as benefit from preventive and therapeutic efforts. As new knowledge and tools in molecular genetics become available, there is an urgent need for large population-based registries of families at high risk for cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8722746     DOI: 10.1002/(SICI)1098-2272(1996)13:2<193::AID-GEPI5>3.0.CO;2-9

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  6 in total

1.  Disparities in cancer screening in individuals with a family history of breast or colorectal cancer.

Authors:  Ninez A Ponce; Jennifer Tsui; Sara J Knight; Aimee Afable-Munsuz; Uri Ladabaum; Robert A Hiatt; Jennifer S Haas
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

2.  Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.

Authors:  L S Friedman; S A Gayther; T Kurosaki; D Gordon; B Noble; G Casey; B A Ponder; H Anton-Culver
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

3.  Race and family history assessment for breast cancer.

Authors:  Harvey J Murff; Daniel Byrne; Jennifer S Haas; Ann Louise Puopolo; Troyen A Brennan
Journal:  J Gen Intern Med       Date:  2005-01       Impact factor: 5.128

4.  Cancer family history reporting: impact of method and psychosocial factors.

Authors:  Kimberly M Kelly; Randi Shedlosky-Shoemaker; Kyle Porter; Amber Remy; Philip DeSimone; Michael A Andrykowski
Journal:  J Genet Couns       Date:  2007-02-23       Impact factor: 2.717

5.  Specifying exposure classification parameters for sensitivity analysis: family breast cancer history.

Authors:  Anne M Jurek; Timothy L Lash; George Maldonado
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

6.  Accuracy of self-reported personal history of cancer in an outpatient breast center.

Authors:  Francisco J Dominguez; Christine Lawrence; Elkan F Halpern; Brian Drohan; Georges Grinstein; Dalliah M Black; Barbara L Smith; Michele A Gadd; Michele Specht; Daniel B Kopans; Richard H Moore; Sherwood S Hughes; Constance A Roche; Kevin S Hughes
Journal:  J Genet Couns       Date:  2007-05-17       Impact factor: 2.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.